Summary of results of operations by reportable segment |
| | | | | | | | | | | | | | | Prescription | | Medical | | | | | | | For the six months ended June 30, 2021 | | Medications | | Devices | | Corporate | | Consolidated | Net sales | | $ | 4,850,462 | | $ | 1,682,793 | | $ | — | | $ | 6,533,255 | Cost of goods sold | | | 562,328 | | | 474,352 | | | — | | | 1,036,680 | Selling, general and administrative expenses | | | 3,666,993 | | | 1,291,426 | | | 3,039,471 | | | 7,997,890 | Research and development expenses | | | 519,227 | | | — | | | — | | | 519,227 | Depreciation and amortization expense | | | 2,796,539 | | | 661,118 | | | — | | | 3,457,657 | Change in fair value of derivative liability | | | — | | | — | | | (7,670,000) | | | (7,670,000) | Interest expense | | | — | | | — | | | 288,937 | | | 288,937 | Income tax expense | | | — | | | (6,700) | | | — | | | (6,700) | Net income (loss) | | $ | (2,694,625) | | $ | (750,803) | | $ | 4,341,592 | | $ | 896,164 |
| | | | | | | | | | | | | | | Prescription | | Medical | | | | | | | For the six months ended June 30, 2020 | | Medications | | Devices | | Corporate | | Consolidated | Net sales | | $ | 1,538,543 | | $ | 1,626,942 | | $ | — | | $ | 3,165,485 | Cost of goods sold | | | 777,594 | | | 545,672 | | | — | | | 1,323,266 | Selling, general and administrative expenses | | | 4,820,367 | | | 1,213,864 | | | 2,841,931 | | | 8,876,162 | Research and development expense | | | 270,968 | | | — | | | — | | | 270,968 | Depreciation and amortization expense | | | 2,707,181 | | | 615,541 | | | — | | | 3,322,722 | Interest expense | | | — | | | — | | | 1,263,709 | | | 1,263,709 | Income tax benefit | | | — | | | 43,752 | | | — | | | 43,752 | Net loss | | $ | (7,037,567) | | $ | (704,383) | | $ | (4,105,640) | | $ | (11,847,590) |
|
Summary of net sales by geographic region |
| | | | | | | | | | | | | | | For the Three Months Ended | | For the Six Months Ended | | | June 30, | | June 30, | Net sales | | 2021 | | 2020 | | 2021 | | 2020 | United States | | $ | 2,188,789 | | $ | 1,205,973 | | $ | 5,893,312 | | $ | 2,654,593 | International | | | 268,860 | | | 167,591 | | | 639,943 | | | 510,892 | | | $ | 2,457,649 | | $ | 1,373,564 | | $ | 6,533,255 | | $ | 3,165,485 |
|
Summary of assets by reportable segment and reconciliation of segment assets to consolidated assets |
| | | | | | | | | | | | Prescription | | | | | | | | | Medications | | Medical Devices | | Consolidated | Intangible assets, net | | $ | 21,834,257 | | $ | 6,874,115 | | $ | 28,708,372 | Total segment assets | | $ | 47,850,814 | | $ | 8,819,430 | | $ | 56,670,244 |
| | | | | | | | | | | | Prescription | | | | | | | | | Medications | | Medical Devices | | Consolidated | Intangible assets, net | | $ | 24,625,686 | | $ | 7,535,233 | | $ | 32,160,919 | Total segment assets | | $ | 60,725,191 | | $ | 9,128,823 | | $ | 69,854,014 |
|